On Sept. 7, 2021, Takeda Pharmaceutical announced the Government of Japan’s Ministry of Health, Labour and Welfare purchase of 150 million doses of Novavax vaccine candidate (TAK-019 in Japan) manufactured in Japan by Takeda subject to licensing and approval. The details of the terms and conditions of the agreement were confidential.